As it is poor prognosis for both CD20 negative DLBCL and DLBCL with dual expression of BCL-2 and MYC, CD20-negative DLBCL with BCL-2 and MYC double expression is expected to have a worse prognosis. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.